**Supplementary Table 1: Impacts of pre-CCVD on transplantation outcomes in allo-HCT subgroup****.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Outcomes** | **HR** | **95% CI** | ***P*** |
| Neutrophil engraftment | | | |
| Study cohort | | | |
| Control group | Reference | | |
| pre-CCVD group | 0.839 | 0.480–1.465 | 0.537 |
| Platelet engraftment | | | |
| Study cohort | | | |
| Control group | Reference | | |
| pre-CCVD group | 0.975 | 0550–1.727 | 0.930 |
| Risk of disease | | | |
| Standard | Reference |  |  |
| High | 0.542 | 0310–0.947 | 0.031 |
| Length of stay in laminar-flow ward | | | |
| Study cohort | | | |
| Control group | Reference | | |
| pre-CCVD group | 1.304 | 0.749–2.270 | 0.349 |
| post-CCVD | | | |
| Study cohort | | | |
| Control group | Reference | | |
| pre-CCVD group | 8.500 | 2.140–33.900 | 0.002 |
| Echocardiogram abnormality | | | |
| No | Reference |  |  |
| Yes | 0.138 | 0.025–0.765 | 0.023 |
| Non-relapse mortality | | | |
| Study cohort | | | |
| Control group | Reference |  |  |
| pre-CCVD group | 0.376 | 0.074–1.910 | 0.238 |
| OS | | | |
| Study cohort | | | |
| Control group | Reference |  |  |
| pre-CCVD group | 0.780 | 0.315–1.931 | 0.591 |
| Cumulative chemotherapy cycles | | | |
| ＜6 | Reference |  |  |
| ≥6 | 1.989 | 1.019–3.882 | 0.044 |
| DFS | | | |
| Study cohort | | | |
| Control group | Reference |  |  |
| pre-CCVD group | 0.943 | 0.415–2.139 | 0.888 |

allo-HCT: Allogeneic hematopoietic cell transplantation; CI: Confidence interval; DFS: Disease-free survival; HR: Hazard ratio; OS: Overall survival; post-CCVD: Posttransplant cardio-cerebrovascular disease; pre-CCVD: Previous cardio-cerebrovascular disease.

**Supplementary Table 2: Impacts of pre-CCVD on transplantation outcomes in auto-HCT subgroup****.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Outcomes** | **HR** | **95% CI** | ***P*** |
| Neutrophil engraftment | | | |
| Study cohort | | | |
| Control group | Reference | | |
| pre-CCVD group | 0.839 | 0480–1.465 | 0.537 |
| Platelet engraftment | | | |
| Study cohort | | | |
| Control group | Reference | | |
| pre-CCVD group | 0.608 | 0.233–1.587 | 0.309 |
| Length of stay in laminar-flow ward | | | |
| Study cohort | | | |
| Control group | Reference | | |
| pre-CCVD group | 0.712 | 0.269–1.883 | 0.493 |
| Non-relapse mortality | | | |
| Study cohort | | | |
| Control group | Reference |  |  |
| pre-CCVD group | 0.791 | 0.193–3.240 | 0.744 |
| OS | | | |
| Study cohort | | | |
| Control group | Reference |  |  |
| pre-CCVD group | 1.112 | 0.121–10.190 | 0.925 |
| DFS | | | |
| Study cohort | | | |
| Control group | Reference |  |  |
| pre-CCVD group | 0.219 | 0.026–1.863 | 0.165 |
| Disease stage before HCT | | | |
| CR1/CR2 | Reference |  |  |
| Relapse/Refractory | 6.085 | 1.781–20.790 | 0.003 |

auto-HCT: Autologous hematopoietic cell transplantation; CI: Confidence intervals; CR: Complete remission; DFS: Disease-free survival; HCT: Hematopoietic cell transplantation; HR: Hazard ratio; OS: Overall survival; pre-CCVD: Previous cardio-cerebrovascular disease.